RecruitingNot ApplicableNCT06935305

OSNA Versus Ultrastaging to Detect Sentinel Lymph Node Metastasis in Endometrial Cancer

One Step Nucleic Acid Amplification (OSNA) Versus Ultrastaging to Detect Sentinel Lymph Node Metastasis in Endometrial Cancer: a Randomized, Multicenter, Controlled Trial (SENT-OSNA Study)


Sponsor

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Enrollment

1,922 participants

Start Date

Jul 30, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

Patients enrolled in the study will be randomized before surgery: in one study arm, the search for lymph node metastases in surgically removed sentinel lymph nodes will occur using the ultrastaging method (standard), while in the other arm it will be conducted using the OSNA method.


Eligibility

Sex: FEMALE

Inclusion Criteria4

  • Histologically confirmed endometrial cancer
  • Apparent (pre-operative) FIGO stage I-II
  • Radical surgery
  • Attempt of SLN mapping

Exclusion Criteria7

  • Uterine sarcoma (including endometrial stromal sarcoma)
  • Fertility sparing surgery
  • Dedifferentiated histology
  • Undifferentiated histology
  • Neoadjuvant therapy
  • Previous surgery to pelvic lymph nodes
  • Lymph nodes with short axis \>15 mm at pre-operative imaging

Interventions

DEVICEOSNA

The search for lymph node metastases in surgically removed sentinel lymph nodes will occur using the OSNA method

DEVICEUltrastaging

The search for lymph node metastases in surgically removed sentinel lymph nodes will occur using the ultrastaging method


Locations(1)

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Rome, Italy, Italy

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06935305


Related Trials